Gut Microbiota and its Role in Enhancing the Efficacy of Diabetes Therapies

Clicks: 1
ID: 309191
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #134 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Multiple studies show gut microbiota modulation represents a vital method for diabetes mellitus treatment which strengthens therapeutic performance. The metabolic functions and immune regulation and gut barrier maintenance capabilities of gut microbiota contribute to the development of type 1 and type 2 diabetes. The process of dysbiosis which generates improper microbial composition creates long- lasting inflammation and results in insulin resistance and glucose intolerance. The article reviews the effects of gut microbiota on diabetes Mellitus medicine treatments by examining oral hypoglycemic agents and insulin sensitivity methods and non-drug interventions such as dietary adjustments and probiotics usage. Premise-based therapy and FMT interventions demonstrate strong potential in both restoring microbiome equilibrium and enhancing blood sugar control. Research should continue because the individual differences in microbiota shapes need additional study as do safety risks when using these interventions. The optimization of microbiome-based approaches will be possible with emerging technology in metagenomics alongside advances in artificial intelligence and precision medicine. In this review, we explore the intricate relationship between gut microbiota and diabetes therapies, emphasizing its potential to enhance treatment efficacy and improve patient outcomes. Future research should focus on developing targeted microbiota-based interventions and ensuring their long-term safety to fully harness their therapeutic potential in diabetes care.
Reference Key
imported_1761926623_6904dddfdaae6 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Swadesh Kumar Pattanik
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2025
DOI
DOI not found
URL
https://ijpdd.org/index.php/files/article/view/254
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.